Is survival really better after repeated lung metastasectomy?


Journal

Clinical & experimental metastasis
ISSN: 1573-7276
Titre abrégé: Clin Exp Metastasis
Pays: Netherlands
ID NLM: 8409970

Informations de publication

Date de publication:
02 2021
Historique:
received: 25 09 2020
accepted: 23 10 2020
pubmed: 30 10 2020
medline: 29 6 2021
entrez: 29 10 2020
Statut: ppublish

Résumé

Several groups have observed that average survival time after a second lung metastasectomy is longer than after a first metastasectomy. The randomised controlled trial Pulmonary Metastasectomy in Colorectal Cancer (PulMiCC) found no survival benefit from lung metastasectomy. In fact, median survival was longer, and four-year overall survival was higher, in the control group than in those randomly assigned to metastasectomy, although not significantly so. The illusion of benefit is because survival without metastasectomy has been assumed to be near zero, as stated in Society of Thoracic Surgeons' Expert Consensus Document on Pulmonary Metastasectomy 2019. It has been repeatedly found that survival is influenced by the selection of patients who have characteristics associated with better prognosis. The passage of time while monitoring and assessing patients, and observing their rate of progression, provides for immortal time bias. Reselection of the most favourable patients for repeated metastasectomy is the likely reason for any differences in survival between first and repeated metastasectomy operations.

Identifiants

pubmed: 33119884
doi: 10.1007/s10585-020-10061-z
pii: 10.1007/s10585-020-10061-z
doi:

Types de publication

Letter Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

73-75

Subventions

Organisme : Cancer Research UK
ID : 11393
Pays : United Kingdom

Références

Forster C, Ojanguren A, Perentes JY, Zellweger M, Federici S, Krueger T et al (2020) Is repeated pulmonary metastasectomy justified? Clin Exp Metastasis. https://doi.org/10.1007/s10585-020-10056-w
doi: 10.1007/s10585-020-10056-w pubmed: 32920725 pmcid: 7665970
Treasure T, Mineo T, Ambrogi V, Fiorentino F (2015) Survival is higher after repeat lung metastasectomy than after a first metastasectomy: Too good to be true? J Thorac Cardiovasc Surg 149(5):1249–1252
doi: 10.1016/j.jtcvs.2015.01.067
Morris E, Treasure T (2017) If a picture is worth a thousand words, take a good look at the picture: survival after liver metastasectomy for colorectal cancer. Cancer Epidemiol 49:152–155
doi: 10.1016/j.canep.2017.06.009
Milosevic M, Edwards J, Tsang D, Dunning J, Shackcloth M, Batchelor T et al (2020) Pulmonary Metastasectomy in Colorectal Cancer (PulMiCC): Updated analysis of 93 randomised patients—control survival is much better than previously assumed. Colorectal Dis. https://doi.org/10.1111/codi.15113
doi: 10.1111/codi.15113 pubmed: 33002305
Macbeth F, Fallowfield L (2020) The myth of pulmonary metastasectomy. Br J Cancer 123(4):499–500
doi: 10.1038/s41416-020-0927-2

Auteurs

Francesca Fiorentino (F)

Department of Surgery and Cancer, Imperial College London, London, UK.

Tom Treasure (T)

Clinical Operational Research Unit, University College London, London, UK. tom.treasure@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH